

Liang Peng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7986463/publications.pdf>

Version: 2024-02-01

13
papers

162
citations

1040056

9
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

250
citing authors

#	ARTICLE	IF	CITATIONS
1	The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2019, 14, 9.	2.7	22
2	The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20181031.	2.2	20
3	Thyroid doseâ€volume thresholds for the risk of radiationâ€related hypothyroidism in nasopharyngeal carcinoma treated with intensityâ€modulated radiotherapyâ€”A singleâ€institution study. <i>Cancer Medicine</i> , 2019, 8, 6887-6893.	2.8	19
4	Relationship between pretreatment concentration of plasma Epsteinâ€Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation. <i>Cancer Medicine</i> , 2018, 7, 5988-5998.	2.8	18
5	Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort. <i>Oral Oncology</i> , 2019, 89, 102-106.	1.5	16
6	A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 551255.	2.8	13
7	Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 Patients. <i>Journal of Cancer</i> , 2017, 8, 1238-1248.	2.5	12
8	Necessity of concurrent chemotherapy in N2â€3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of 3 cycles followed by intensityâ€modulated radiotherapy. <i>Cancer Medicine</i> , 2019, 8, 2823-2831.	2.8	12
9	The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses. <i>Journal of Cancer</i> , 2018, 9, 4510-4520.	2.5	9
10	A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage IIâ€IVA nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2018, 86, 258-265.	1.5	6
11	Treatment effects of cumulative cisplatin dose during radiotherapy following induction chemotherapy in nasopharyngeal carcinoma: propensity score analyses. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093742.	3.2	5
12	Evolving landscape and academic attitudes toward the controversies of global immunoâ€oncology trials. <i>International Journal of Cancer</i> , 2021, 149, 108-118.	5.1	5
13	Progressionâ€free survival assessed per immuneâ€related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immuneâ€checkpoint inhibitors in lung cancer: A systematic review and metaâ€analysis. <i>Cancer Medicine</i> , 2021, 10, 8272-8287.	2.8	5